Lynette Keyes-Elstein
Overview
Explore the profile of Lynette Keyes-Elstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wareing N, Wang X, Keyes-Elstein L, Goldmuntz E, Lyons M, McSweeney P, et al.
Arthritis Rheumatol
. 2024 Mar;
76(8):1288-1293.
PMID: 38497141
Objective: In the randomized Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial, myeloablation, followed by hematopoietic stem cell transplantation (HSCT), led to the normalization of systemic sclerosis (SSc) peripheral blood cell (PBC)...
2.
Chakravarty E, Utset T, Kamen D, Contreras G, McCune W, Aranow C, et al.
Lancet Rheumatol
. 2024 Feb;
6(3):e168-e177.
PMID: 38301682
Background: Mycophenolate mofetil is an immunosuppressant commonly used to treat systemic lupus erythematosus (SLE) and lupus nephritis. It is a known teratogen associated with significant toxicities, including an increased risk...
3.
Ayoglu B, Donato M, Furst D, Crofford L, Goldmuntz E, Keyes-Elstein L, et al.
Ann Rheum Dis
. 2023 Jan;
82(5):670-680.
PMID: 36653124
Objectives: Results from the SCOT (Scleroderma: Cyclophosphamide Or Transplantation) clinical trial demonstrated significant benefits of haematopoietic stem cell transplant (HSCT) versus cyclophosphamide (CTX) in patients with systemic sclerosis. The objective...
4.
Adamska J, Zia A, Bloom M, Crofford L, Furst D, Goldmuntz E, et al.
Ann Rheum Dis
. 2022 Oct;
82(3):357-364.
PMID: 36241361
Objectives: Myeloablative autologous haematopoietic stem cell transplant (HSCT) was recently demonstrated to provide significant benefit over cyclophosphamide (CYC) in the treatment of diffuse cutaneous systemic sclerosis (dcSSc) in the Scleroderma:...
5.
Greenbaum C, Serti E, Lambert K, Weiner L, Kanaparthi S, Lord S, et al.
JCI Insight
. 2021 Nov;
6(21).
PMID: 34747368
BackgroundIL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of...
6.
Keyes-Elstein L, Pinckney A, Goldmuntz E, Welch B, Franks J, Martyanov V, et al.
Arthritis Care Res (Hoboken)
. 2021 Sep;
75(2):307-316.
PMID: 34533286
Objective: Among individuals with systemic sclerosis (SSc) randomized to cyclophosphamide (CYC) (n = 34) or hematopoietic stem cell transplantation (HSCT) (n = 33), we examined longitudinal trends of clinical, pulmonary...
7.
Meednu N, Barnard J, Callahan K, Coca A, Marston B, Thiele R, et al.
Arthritis Rheumatol
. 2021 Aug;
74(2):200-211.
PMID: 34347945
Objective: B cells can become activated in germinal center (GC) reactions in secondary lymphoid tissue and in ectopic GCs in rheumatoid arthritis (RA) synovium that may be tumor necrosis factor...
8.
Zamanian R, Pinckney A, Domsic R, Medsger T, Keyes-Elstein L, Sweatt A, et al.
Am J Respir Crit Care Med
. 2021 Jun;
204(3):377-378.
PMID: 34107229
No abstract available.
9.
Zamanian R, Badesch D, Chung L, Domsic R, Medsger T, Pinckney A, et al.
Am J Respir Crit Care Med
. 2021 Mar;
204(2):209-221.
PMID: 33651671
Systemic sclerosis (SSc)-pulmonary arterial hypertension (PAH) is one of the most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis. We investigated the safety and efficacy...
10.
Bellocchi C, Ying J, Goldmuntz E, Keyes-Elstein L, Varga J, Hinchcliff M, et al.
Arthritis Rheumatol
. 2020 Nov;
73(4):660-670.
PMID: 33131208
Objective: To provide a large-scale assessment of serum protein dysregulation in diffuse cutaneous systemic sclerosis (dcSSc) and to investigate serum protein correlates of SSc fibrotic features. Methods: We investigated serum...